[{"address1": "Ugland House", "address2": "PO Box 309", "city": "Grand Cayman", "zip": "KY1-1104", "country": "Cayman Islands", "phone": "848-230-7430", "website": "https://www.adlainortye.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.", "fullTimeEmployees": 123, "companyOfficers": [{"maxAge": 1, "name": "Mr. Yang  Lu", "age": 43, "title": "Co- Founder, CEO & Chairman", "yearBorn": 1981, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kaiyang  Tang", "age": 59, "title": "President", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Xiaofeng  Ye Ph.D.", "age": 45, "title": "Interim CFO and VP of Business Development & Commercialization Strategy", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ngai Chiu  Tse M.D., Ph.D.", "age": 57, "title": "Head of Research & Development", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.8, "open": 1.8212, "dayLow": 1.71, "dayHigh": 1.8212, "regularMarketPreviousClose": 1.8, "regularMarketOpen": 1.8212, "regularMarketDayLow": 1.71, "regularMarketDayHigh": 1.8212, "payoutRatio": 0.0, "beta": -0.876, "forwardPE": -1.111111, "volume": 125, "regularMarketVolume": 125, "averageVolume": 9392, "averageVolume10days": 13580, "averageDailyVolume10Day": 13580, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 65313472, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 3.89, "allTimeHigh": 19.3, "allTimeLow": 1.1, "priceToSalesTrailing12Months": 33.666737, "fiftyDayAverage": 1.66138, "twoHundredDayAverage": 1.887025, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 165328448, "profitMargins": 0.0, "floatShares": 59847067, "sharesOutstanding": 31236934, "sharesShort": 1283, "sharesShortPriorMonth": 9861, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.0, "heldPercentInsiders": 0.0859, "heldPercentInstitutions": 0.00191, "shortRatio": 0.11, "shortPercentOfFloat": 0.0, "impliedSharesOutstanding": 36900300, "bookValue": 0.691, "priceToBook": 2.6049204, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -51869000, "trailingEps": -1.7, "forwardEps": -1.62, "enterpriseToRevenue": 85.221, "enterpriseToEbitda": -3.184, "52WeekChange": -0.100000024, "SandP52WeekChange": 0.17741585, "quoteType": "EQUITY", "currentPrice": 1.8, "recommendationKey": "none", "totalCash": 61159000, "totalCashPerShare": 0.552, "ebitda": -51924000, "totalDebt": 27226000, "quickRatio": 1.349, "currentRatio": 1.412, "totalRevenue": 1940000, "debtToEquity": 106.831, "revenuePerShare": 0.061, "returnOnAssets": -0.32840002, "returnOnEquity": -1.0319, "grossProfits": 1940000, "freeCashflow": -30614000, "operatingCashflow": -51819000, "revenueGrowth": 1.18, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -12.208759, "financialCurrency": "USD", "symbol": "ANL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 0.0, "regularMarketPrice": 1.8, "fiftyTwoWeekRange": "1.1 - 3.89", "fiftyTwoWeekHighChange": -2.0900002, "fiftyTwoWeekHighChangePercent": -0.5372751, "fiftyTwoWeekChangePercent": -10.000002, "earningsTimestampStart": 1754650740, "earningsTimestampEnd": 1755864000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.7, "epsForward": -1.62, "epsCurrentYear": -0.36, "priceEpsCurrentYear": -4.9999995, "fiftyDayAverageChange": 0.1386199, "fiftyDayAverageChangePercent": 0.0834366, "twoHundredDayAverageChange": -0.08702505, "twoHundredDayAverageChangePercent": -0.04611759, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-09-29", "cryptoTradeable": false, "shortName": "Adlai Nortye Ltd.", "longName": "Adlai Nortye Ltd.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1695994200000, "regularMarketChange": 0.0, "regularMarketDayRange": "1.71 - 1.8212", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 9392, "fiftyTwoWeekLowChange": 0.6999999, "fiftyTwoWeekLowChangePercent": 0.63636357, "corporateActions": [], "regularMarketTime": 1759348800, "exchange": "NGM", "messageBoardId": "finmb_1830112145", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "REGULAR", "displayName": "Adlai Nortye", "trailingPegRatio": null, "__fetch_time": "2025-10-02"}]